



1st International Congress of
Micro-Immunotherapy
18-20 May 2017, Mallorca, Spain

PRESS RELEASE

Update on ICoMI 2017

Micro-immunotherapy, a path towards treatment for autoimmune diseases



ICoMI 2017, which was held in Palma de Mallorca in May, brought researchers, scientists, and immunologists from all over the world (Australia, the United States, Europe, Japan) together for the first time. ICoMI facilitated collaboration between basic research stakeholders and clinical experts to further elevate scientific discussion.

Studies and collaborations initiated at the close of ICoMI 2017:

Optimization of immune system restoration to allow faster post-surgery recovery for patients:

Professor Michael Stark, President of the New European Surgical Academy (NESA), an association of surgeons specialized in gynaecology and oncology, and the Spanish Association of Micro-Immunotherapy (AEMI) will work together on the development of a combination between surgery, immune restoration, and immunomodulation.

Evaluation on the impact of cytokines in low doses in mice with human multiple sclerosis disease models:

Collaboration between the University of Barcelona and Dr. Pascal Mensah, Scientific Director of ICoMI 2017.

Impact of cytokines in low doses in caring for diabetes:

Collaboration between a team of researchers in Melbourne and Micro-immunotherapy associations.

Additionally, preliminary studies have already been conducted to demonstrate the positive impact of low-dose cytokines on the activity of certain enzymes that prolong chromosome life: telomerase.

Conclusion:

The inaugural ICoMI, which brought together over 28 nationalities and more than 300 participants, made it possible to go from a period of observation and medical analysis to a fundamental period of scientific expertise by demonstrating the benefit of weak immuno-modulatory doses in caring for autoimmune diseases, and also for more common diseases such as eczema or asthma, which are linked to immune system disorders.

After the inaugural ICoMI, micro-immunotherapy associations will publish in scientific journals, in collaboration with international teams of researchers and universities, to present their scientific discoveries. These collaborations aim to present micro-immunotherapy as the future for autoimmune disease treatments, thus improving patient care.



1st International Congress of
Micro-Immunotherapy
18-20 May 2017, Mallorca, Spain

About micro-immunotherapy:

Three associations contribute to the development of micro-immunotherapy worldwide, located in France, Spain, and Germany/Austria. These associations bring together doctors who team up to integrate immunological reasoning into daily disease diagnosis and treatment.

The idea of using immuno-competent substances in low-doses (low molar concentrations ranging from micrograms to femtograms) was contributed over 50 years ago by Dr. Maurice Jenaer, today considered as the father of micro-immunotherapy. Trained in homeopathy, Dr. Jenaer used interleukins, cytokines, or low-dose growth factors to positively modulate the immune system of his patients.

For over 25 years, low-dose immuno-competent products have been created and developed to offer doctors a new therapeutic tool to treat autoimmune diseases, including more common diseases such as eczema or asthma, or any disease in which the immune system is involved.

Doctors have launched their own observations and clinical case studies to evaluate these low-dose treatments and

to determine which ones were effective or not for a given disease. There was a long 25-year period of experimentation and recognition before it was possible to conduct further clinical studies to confirm or invalidate certain immunological therapies.

Low-dose micro-immunotherapy is still in early stages, with larger studies having started in the late 2000s and further work and studies expected.

These medical associations came together at the inaugural International Congress of Micro-Immunotherapy (ICoMI 2017), and brought together scientists prescribing micro-immunotherapy treatments in low doses from around the world.

Press Contacts:
palm'action

Nathalie D'amico
Tel: +33 (0) 608 578 211
nathalie@palmaction.com

Jean-Yves Goar
Tel: +33 (0) 686 200 168
jean-yves@goar.fr

Contact : ICoMI

info@icomi2017.org
www.icomi2017.org